Herpes simplex virus 1 (HSV-1) causes a chronic, lifelong infection in >60% of adults and there is currently no cure. The standard treatment Acyclovir can relieve symptoms and marginally shorten outbreaks if taken in time, but not eliminate the virus.
Vironova Medical's anti-herpes compound
We are developing a topical ointment containing the active ingredient B-220 for treatment of Herpes labialis – an infection caused by herpes simplex virus-1 (HSV-1).
Herpes - a lifelong disease
IN THE UNITED STATES, IT IS ESTIMATED THAT APPROXIMATELY 500,000 NEW HSV-1 INFECTIONS OCCUR EVERY YEAR.
Antiviral effect of B-220
Vironova Medical´s compound B-220, first discovered over 4 decades ago, demonstrates a potent broad-spectrum antiviral activity against several viruses from the herpes family i.e. HSV-1, HSV-2, Cytomegalovirus (CMV) and Varicella zoster virus (VZV). It appears to inhibit viral replication at different stages of the virus life cycle, and is more effective compared to Acyclovir. B-220 is approved for topical administration in a US patent.